ATE126530T1 - Monoklonale antikörper gegen linsenepithelzellen und methoden zur verhinderung des vermehrung übriggebliebener linsenepithelzellen nach extrakapsuläres extraktion. - Google Patents

Monoklonale antikörper gegen linsenepithelzellen und methoden zur verhinderung des vermehrung übriggebliebener linsenepithelzellen nach extrakapsuläres extraktion.

Info

Publication number
ATE126530T1
ATE126530T1 AT89907912T AT89907912T ATE126530T1 AT E126530 T1 ATE126530 T1 AT E126530T1 AT 89907912 T AT89907912 T AT 89907912T AT 89907912 T AT89907912 T AT 89907912T AT E126530 T1 ATE126530 T1 AT E126530T1
Authority
AT
Austria
Prior art keywords
epithelial cells
lens
lens epithelial
methods
monoclonal antibodies
Prior art date
Application number
AT89907912T
Other languages
English (en)
Inventor
Jared M Emery
Dominic M-K Lam
Peter J Kelleher
Original Assignee
Baylor College Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/204,168 external-priority patent/US4871350A/en
Priority claimed from US07/206,610 external-priority patent/US5202252A/en
Application filed by Baylor College Medicine filed Critical Baylor College Medicine
Application granted granted Critical
Publication of ATE126530T1 publication Critical patent/ATE126530T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT89907912T 1988-06-08 1989-06-08 Monoklonale antikörper gegen linsenepithelzellen und methoden zur verhinderung des vermehrung übriggebliebener linsenepithelzellen nach extrakapsuläres extraktion. ATE126530T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/204,168 US4871350A (en) 1986-11-04 1988-06-08 Methods and compositions for preventing secondary cataracts
US07/206,610 US5202252A (en) 1982-03-05 1988-06-14 Monoclonal antibodies against lens epithelial cells and methods for preventing proliferation of remnant lens epithelial cells after extracapsular extraction

Publications (1)

Publication Number Publication Date
ATE126530T1 true ATE126530T1 (de) 1995-09-15

Family

ID=26899251

Family Applications (1)

Application Number Title Priority Date Filing Date
AT89907912T ATE126530T1 (de) 1988-06-08 1989-06-08 Monoklonale antikörper gegen linsenepithelzellen und methoden zur verhinderung des vermehrung übriggebliebener linsenepithelzellen nach extrakapsuläres extraktion.

Country Status (9)

Country Link
EP (1) EP0372071B1 (de)
JP (1) JP2677438B2 (de)
KR (1) KR960005732B1 (de)
AT (1) ATE126530T1 (de)
AU (1) AU623666B2 (de)
DE (1) DE68923852T2 (de)
DK (1) DK34190A (de)
FI (1) FI94258C (de)
WO (1) WO1989012093A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995033492A1 (en) * 1994-06-09 1995-12-14 Houston Biotechnology Incorporated Methods and compositions for modulation of wound healing
DE102004021754A1 (de) 2004-04-30 2005-11-24 Reinhardt Thyzel Vorrichtung zum Entfernen von Epithelzellen aus einem Linsenkapselsack eines menschlichen oder tierischen Auges
WO2005117987A1 (en) * 2004-06-01 2005-12-15 Glazier Alan N Antibody conjugates targeting to ocular proteins
US20050265937A1 (en) * 2004-06-01 2005-12-01 Alan Glazier Systems and methods for changing eye color appearance

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4432751A (en) * 1982-03-05 1984-02-21 Baylor College Of Medicine Monoclonal antibodies against lens epithelial cells and preventing proliferation of remnant lens epithelial cells after extracapsular extraction

Also Published As

Publication number Publication date
FI94258C (fi) 1995-08-10
AU3850989A (en) 1990-01-05
JP2677438B2 (ja) 1997-11-17
JPH03501806A (ja) 1991-04-25
KR900702004A (ko) 1990-12-05
FI94258B (fi) 1995-04-28
AU623666B2 (en) 1992-05-21
WO1989012093A1 (en) 1989-12-14
EP0372071A4 (de) 1990-06-26
EP0372071B1 (de) 1995-08-16
DE68923852T2 (de) 1995-12-21
FI900630A0 (fi) 1990-02-08
DK34190D0 (da) 1990-02-08
EP0372071A1 (de) 1990-06-13
DK34190A (da) 1990-04-06
KR960005732B1 (ko) 1996-05-01
DE68923852D1 (de) 1995-09-21

Similar Documents

Publication Publication Date Title
DE69122962D1 (de) Intraokulare linse sowie verfahren zum herstellen derselben
DK486282A (da) Fremgangsmaade til fremstilling af 5- eller 6-hydroxy-2-benzothiazolsulfonamider
DE69007691D1 (de) Verfahren zur Herstellung von Alkylaluminoxanen.
GB8808067D0 (en) Method of artificial intraocular lens device for phakic treatment of myopia
ATE147613T1 (de) Synthetisches material, das die anlagerung, das wachstum und die befestigung von epithelzellen fördert, prosthetische vorrichtung zur subepithelialen implantation sowie behandelte linse
NL7900676A (nl) Werkwijze voor de vervaardiging van kunstmatige bloedvatprothesen en kunstmatige bloedvatprothese.
DE69030100D1 (de) Peptidderivat, verfahren zu dessen herstellung, sowie dieses enthaltende pharmazeutische zusammensetzung
DE69129460D1 (de) Verwendung von Anti-ICAM Antikörpern zur Herstellung eines Präparats für die BEHANDLUNG VON ENDOTOXINSCHOCK
DE69214121D1 (de) Verfahren zur Herstellung von Intraokularlinsen
CH609859A5 (en) Lens as a substitute for the natural lens surgically removed from the eye of a living being
EP0350690A3 (de) Neutralisation der in vitro- und in vivo-toxischen Eigenschaften von TNF-alfa durch monoklonale Antikörper und die davon abgeleiteten Fragmente
ATE7138T1 (de) Verfahren zur herstellung von 1,5-didesoxy-1,5imino-d-glucitol und dessen n-derivaten.
DK230590D0 (da) Sproejte til brug ved kataraktkirurgi
EP0444951A3 (en) Process for forming intraocular lenses having haptics with high fracture toughness
DE59008850D1 (de) Verfahren zur Herstellung von Brustprothesen.
ATE126530T1 (de) Monoklonale antikörper gegen linsenepithelzellen und methoden zur verhinderung des vermehrung übriggebliebener linsenepithelzellen nach extrakapsuläres extraktion.
DE69010733D1 (de) Verfahren zur Herstellung eines Alkylmethacrylates.
GB1550418A (en) Method of making artificial intraocular lenses
GB1552816A (en) Method of making artificial intraocular lenses
DE68915387D1 (de) Verfahren zur Herstellung von ethylenischen Pfropfcopolymeren.
DE3890771T1 (de) Intraokularlinse zur korrektion von ametropie
FI916000A0 (fi) Ett saett rengoera proteiner.
ATE43610T1 (de) Acino-foetale differenzierungsproteine verbunden mit krebs des pankreas, antiserum und monoklonale antikoerper gegen diese proteine und verfahren zu ihrer herstellung.
ATE206456T1 (de) Impstoff gegen krankheitserreger, zusammensetzung zur behandlung und vorbeugung von hiv infektionen
SU430854A1 (ru) Способ лечения ожогов глаз

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee